Izrael - hebrajski - Ministry of Health

אופק פריידס בע"מ - רופא שיניים

Izrael - hebrajski - Ministry of Health

שילה חדשנות רפואית בע"מ - רופא - תומכונים ואסקולאריים וצנטרי בלון,רשתות שונות לתיקון בקע טבורי,בטני ומפשעתי,קופסאות נקז לניתוחי חזה,גראפטים לכלי דם,בלונים רכים להזלפת תרופות מדללות טרומבוזים

Izrael - hebrajski - Ministry of Health

גאמידה בע"מ - רופא - היצרות בעורק הקורונרי כאשר יש ספק בצורך לטפל בה

Izrael - hebrajski - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - misoprostol - טבליה - misoprostol 200 mcg - misoprostol - misoprostol - for the treatment of duodenal and gastric ulcer.treatment and prevention nsaid induced ulcers lesions, erosions, while nsaid therapy continues.use in conjunction with mifepristone subject to the approval of a committee for the termination of pregnancy according to the israeli penal law 1977.first-trimester pregnancy failure: use is intended for emptying the uterus in states of first trimester pregnancy failure, including: presentation of a pregnancy sac in the uterus with no fetal echo, missed abortion (until week 11+6 and a fetus 40 mm in length) or incomplete abortion. the preparation is to be used after location of the sac in the uterus has been proved and the diagnosis of pregnancy failure is certain. the preparation can be used for this purpose in an ambulatory setting. the dosage and route of administration will be similar to the use of cytotec in pregnancy termination after using mifegyne. informed consent and medical surveillance are required.softening and dilation of the cervix for performing intraut

Izrael - hebrajski - Ministry of Health

pfizer pharmaceuticals israel ltd - taliglucerase alfa - אבקה להכנת תמיסה לאינפוזיה - taliglucerase alfa 200 u/vial - taliglucerase alfa - taliglucerase alfa - elelyso (taliglucerase alfa ) for injection is a hydrolytic lysosomal glucocerebroside - specific enzyme indicated for long - term enzyme replacement therapy (ert) for adults with a confirmed diagnosis of type 1 gaucher disease.

Izrael - hebrajski - Ministry of Health

pfizer pharmaceuticals israel ltd - eplerenone 25 mg - film coated tablets - eplerenone - inspra is indicated, in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (lvef < 40 % ) and clinical evidence of heart failure after recent myocardial infarction.

Izrael - hebrajski - Ministry of Health

pfizer pharmaceuticals israel ltd - eplerenone 50 mg - film coated tablets - eplerenone - inspra is indicated, in addition to standard therapy including beta-blockers, to reduce the risk of cardiovascular mortality and morbidity in stable patients with left ventricular dysfunction (lvef < 40 % ) and clinical evidence of heart failure after recent myocardial infarction.

Izrael - hebrajski - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg; atorvastatin as calcium 10 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

Izrael - hebrajski - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg; atorvastatin as calcium 20 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.

Izrael - hebrajski - Ministry of Health

pfizer pharmaceuticals israel ltd - amlodipine as besylate 5 mg; atorvastatin as calcium 40 mg - film coated tablets - amlodipine - caduet (amlodipine and atorvastatin ) is indicated in patients for whom treatment with both amlodipine and atorvastatin is apptopriate. amlodipine: - hypertension - chronic stable angina - vasospastic angina (prinzmetal's or variant angina). atorvastatin : - prevention of cardiovascular disease - heterozygous familial and nonfamilial hypercholesterolemia - elevated serum tg levels - primary dysbetalipoproteinemia - homozygous familial hypercholesterolemia - pediatric patients (10-17 years of age) : atorvastatin is indicated as an adjunct to diet to reduce total -c ldl-c and apo b levels in boys and postmenarchal girls 10 to 17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: 1. ldl-c remains >or = 190 mg/dl or 2. ldl-c remains > or = 160 mg/dl and: there is a positive family history of premature cardiovascular disease or two or more other cvd risk factors are present in the pediatric patient.